Why Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says AnalystInvestors Business Daily • 03/15/24
Abbott (ABT) Ascends But Remains Behind Market: Some Facts to NoteZacks Investment Research • 03/12/24
Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 03/11/24
Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 DiabetesPRNewsWire • 03/06/24
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the OppositeThe Motley Fool • 03/03/24
3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a DecadeThe Motley Fool • 02/27/24
Abbott (ABT) Up 5.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 02/23/24
Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to KnowZacks Investment Research • 02/22/24